Stay updated with breaking news from Immunization Practices. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The world is entering a new era of vaccines. Following the success of covid-19 mRNA shots, scientists have a far greater capacity to tailor shots to a virus's structure, putting a host of new vaccines on the horizon.
Arexvy shows efficacy in helping protect adults aged 50 to 59 years with an increased risk for respiratory syncytial virus lower respiratory tract disease.
Those who face a high risk of contracting mpox could soon be advised to get routine shots to prevent further outbreaks.
Men who have sex with men and others who are at high risk of mpox infection should get two doses of the Jynneos vaccine, even now that the recent public
Adults over age 60 can now get an RSV shot, but that age group may soon include people in their 50s.